Compare Incyte Corporation (INCY) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Infosys Limited — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Infosys Limited trades at $10.73 (market cap $41.74B). The key difference: Infosys Limited is the larger of the two by market cap, and Infosys Limited pays a 4.89% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Infosys Limited for 27 Days on average.
| INCY | INFY | |
|---|---|---|
Market Cap | $22.85B | $41.74B |
Volume | 1,927,029 | 31,354,285 |
Sector | Health | Technology |
52-Week High | $129.93 | $20.22 |
52-Week Low | $83.80 | $10.49 |
Typical Hold Time | 33 Days | 27 Days |
Enterprise Value | $18.35B | $39.48B |
Dividend Yield | — | 4.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
INFY trades at $10.70, up 1.42% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong profitability with a 16.37% net income margin and ROE of 32.12%. Recent news highlights strategic AI collaborations with Columbia University and ABN Amro. Earnings history shows mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering potential upside. Risks include competitive pressures in IT services and volatile cash flow trends, with net cash flow turning negative in 2026. Analyst sentiment is mixed, with 35% buy ratings but 55% hold, reflecting uncertainty amid steady fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
